Beta Bionics (NASDAQ:BBNX) Stock Rating Upgraded by Leerink Partnrs

Leerink Partnrs upgraded shares of Beta Bionics (NASDAQ:BBNX) to a strong-buy rating in a research note issued to investors on Monday morning,Zacks.com reports.

Several other equities research analysts also recently issued reports on BBNX. Stifel Nicolaus began coverage on shares of Beta Bionics in a research report on Monday. They set a “buy” rating and a $25.00 price objective for the company. LADENBURG THALM/SH SH started coverage on Beta Bionics in a research note on Thursday, February 20th. They set a “neutral” rating and a $20.00 price objective on the stock. Piper Sandler assumed coverage on shares of Beta Bionics in a research note on Monday. They issued an “overweight” rating and a $26.00 target price for the company. Lake Street Capital assumed coverage on shares of Beta Bionics in a report on Monday. They set a “buy” rating and a $30.00 target price for the company. Finally, Robert W. Baird began coverage on shares of Beta Bionics in a research note on Thursday, February 20th. They issued a “neutral” rating and a $20.00 price target on the stock. Three investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Beta Bionics currently has a consensus rating of “Moderate Buy” and an average price target of $24.83.

Beta Bionics Stock Performance

Shares of Beta Bionics stock opened at $20.60 on Monday. Beta Bionics has a 1 year low of $20.00 and a 1 year high of $24.50.

Insider Buying and Selling

In related news, insider Mike Mensinger purchased 33,350 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were bought at an average cost of $17.00 per share, with a total value of $566,950.00. Following the acquisition, the insider now owns 59,019 shares of the company’s stock, valued at $1,003,323. This trade represents a 129.92 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Hadley Harbor Aggre Wellington bought 1,000,000 shares of the firm’s stock in a transaction on Friday, January 31st. The shares were bought at an average cost of $17.00 per share, for a total transaction of $17,000,000.00. Following the purchase, the insider now owns 3,901,599 shares of the company’s stock, valued at approximately $66,327,183. The trade was a 34.46 % increase in their position. The disclosure for this purchase can be found here.

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.